Proud producer of the 2019 BioNJ Dr. Sol J. Barer Award video featuring industry leader Dr. William Hait.
Welcome to the latest edition of the  BioLines Weekender

Last week, BioNJ hosted a Webinar providing an overview of our new Members-only  Health Benefits Plan  --  specifically designed for small- to mid-sized companies with at least two full-time employees. To learn more about the Plan and to see if it meets your organization's needs, click here for a recording of the Webinar. 

Because Patients Can't Wait®, BioNJ is thrilled to host our upcoming conference, entitled "Scientific and Ethical Underpinnings of Gene Transfer/Therapy in Vulnerable Populations:Considerations Supporting Novel Treatments," next Thursday, March 7, at Amicus Therapeutics. Click here to take a look at the robust agenda!

We are now accepting applications to become a Company Presenter at BioNJ's BioPartnering Conference on May 8 in concert with J.P. Morgan and Johnson & Johnson Innovation. The deadline to submit your application is March 27. So, don't delay. 

Additionally, we met with our planning committee for BioNJ's C-Suite Summit taking place November 8. Save the date and look for exciting announcements due out soon. 

Registration is now open for the 2019 BIO International Convention returning to the region June 3-6 at the Pennsylvania Convention Center. Join us in the New Jersey Pavilion and help us showcase the Garden State's vibrant life sciences ecosystem. 

We had the pleasure of touring the South Jersey Technology Park at Rowan University, as well as interviewing Dr. Beena  Sukumaran , Vice President of Research, for BioNJ's Value of Medical Innovation Thought Leadership Series. 

Lastly, BioNJ participated in the 8 2nd edition of the Walk to Washington, aka the Chamber Train, where we met with New Jersey's Congressional Delegation and business leaders.

Because Patients Can't Wait®,
The BioNJ Team

P.S. BioNJ is looking for an Alliance Manager!  Click here  for the job description and let us know if you or an industry colleague is interested in learning more. 

Blue Divider
The 2019 Dr. Sol J. Barer Award Presented to  Dr. William N. Hait
Video produced by  Pulse Productions

During BioNJ's 26th Annual Dinner Meeting and Innovation Celebration, Dr. Sol Barer presented the 12th Annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership to industry icon William N. Hait, M.D., Ph.D. , Global Head, Johnson & Johnson, External Innovation. A globally  recognized expert in translational cancer research, Dr. Hait's work has touched millions of Patients throughout the State and around the world. 

BioNJ is Hiring!

BioNJ, the largest life sciences trade association in NJ, is looking for a dynamic, high-energy Alliance Manager. The work of the Alliance Manager will support BioNJ's face-to-face engagement with stakeholders, such as employers, Patient advocacy groups, hospital groups, healthcare providers, payers and others. Responsibilities will include steering the BioNJ Patient Advocacy Committee, and support of BioNJ's efforts in Trenton and Washington to ensure that a unified, pro-Patient voice is heard by key constituencies. Contact Donna Gibbons at to learn more.

BioNJ Calendar

Scientific and Ethical Underpinnings of Gene Transfer/Therapy in Vulnerable Populations:  Considerations Supporting Novel Treatments
Amicus Therapeutics, Cranbury, NJ
March 7 , 2019
BioNJ BioPartnering Conference
Co-Sponsored by J.P. Morgan and Johnson & Johnson Innovation
The Palace at Somerset Park, Somerset, NJ 08873
May 8, 2019
Register now!

Putting Patients First: The Value of Medical Innovation
Brought to You by Celgene Corporation

Medical innovation enables longer and better quality lives and, in turn, reduces the costs of healthcare. Share with our community how your medical innovation is improving lives and impacting healthcare costs. Send us your Patient and related stories to Plus, click here for valuable tools and resources on the Value of Medical Innovation.

When  Dr. John Marshall  first started treating patients with  pancreatic cancer  nearly 30 years ago, the goal of treatment was to extend a patient's life; the quality of the patient's life was a secondary consideration. Despite some gains in survival for pancreatic cancer, the survival rate is still in the single digits; currently 8.5 percent of patients  are alive five years after diagnosis . While research to  improve treatment options continues , quality of life has become increasingly important.

In the current issue of  Health Affairs , David Wamble and colleagues published a new study --  What's Been The Bang for the Buck? Cost-Effectiveness of Health Care Spending Across Selected Conditions in the U.S . In it, they examined disease-level cost-effectiveness ratios, analyzing changes over time in medical intervention spending and the associated changes in health outcomes of patients with seven different diagnoses. Over the period 1996 to 2015, they found that changes in treatment for patients with lung cancer, ischemic heart disease, cerebrovascular disease, and HIV/AIDS resulted in both cost savings (reduced spending per person) and improved health. 

BioNJ in the News

The 2019 BioNJ Annual Dinner Meeting & Innovation Celebration drew more than 700 biotechnology and pharmaceutical professionals, government officials, academic leaders and professional service providers. New Jersey Governor Phil Murphy provided the opening address, emphasizing the considerable role the State plays in the healthcare ecosystem.

Debbie Hart, CEO and Founding President, BioNJ
For all of the changes in the bio and life sciences sector over the years, Hart has been a constant. And her members are better for it. "This is a sector that has changed dramatically; she is making sure it is changing for the better -- or, more, making sure New Jersey is positioned properly," one insider said.

BioNJ, New Jersey's largest life sciences trade association, announced the election of its 2019 Officers and Board Members. The election preceded BioNJ's 26th Annual Dinner Meeting and Innovation Celebration on February 7. Newly elected Officers include Chairman Christopher J. Schaber, Ph.D., President and Chief Executive Officer, Soligenix, Inc.; Vice Chairman Daniel J. O'Connor, J.D., Chief Executive Officer, OncoSec Medical, Inc.; Treasurer Monika A. Vnuk, M.D., Vice President, R&D Business Development, Pfizer, Inc.; and Secretary Michele Korfin, Chief Commercial Officer, Tyme Technologies, Inc.

BioNJ announced the election of our new Chairman of the Board Christopher J. Schaber, Ph.D., President and Chief Executive Officer, Soligenix, Inc.  "With so many important opportunities and challenges facing the industry, we look forward to working with our new Chairman and all of our officers and Board members as we forge ahead ensuring that New Jersey remains a robust life sciences ecosystem and that innovation and Patient access are empowered," said BioNJ President and CEO Debbie Hart. 

BioNJ is excited to release its 2018 Annual Report Video. As you'll see, 2018 was an extraordinary year for the industry, for New Jersey and for BioNJ!  In Washington, we witnessed some difficult conversations -- and at the same time -- saw a record number of novel drug approvals by the FDA. In New Jersey, we rallied around a Governor who showed his commitment to building our innovation economy. And, we were overjoyed when he brought back and funded the Commission on Science, Innovation and Technology. Through it all, BioNJ has had its finger on the pulse advocating for the industry, medical innovation and for Patients.

NJ Company News

Ever proud of our ecosystem, we are pleased to share our New Jersey Company News. Be sure to click on the article titles below to read the full release.

Cranbury-based BioNJ Member  Amicus Therapeutics  announced that the  U.S. Food and Drug Administration  ( FDA ) has granted to Amicus a  Breakthrough Therapy Designation  to  AT-GAA  for the treatment of late onset  Pompe disease , an inherited lysosomal storage disorder caused by the deficiency of an enzyme known as acid alpha-glucosidase (GAA).  AT-GAA  is the first ever investigational product for Pompe disease to receive BTD. 

Princeton-based BioNJ Member  Taiho Oncology, Inc. announced that the United States Food and Drug Administration (FDA) has approved LONSURF ® as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Princeton-based BioNJ Member Genmab A/S announced topline results from the Phase III COLUMBA study (MMY3012) of subcutaneous (SC) versus intravenous (IV) daratumumab for patients with relapsed or refractory multiple myeloma. The results showed that SC administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 is non-inferior to IV administration of daratumumab with regard to the co-primary end points of overall response rate (ORR) and Maximum Trough concentration (Ctrough ) of daratumumab on day 1 of the third treatment cycle.

Morris Plains-based BioNJ Member Immunomedics, Inc. announced that updated data from the Phase 2 study of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC) were published in the New England Journal of Medicine (NEJM)We are committed to becoming a leading ADC company and this publication in NEJM is a validation of our unique ADC platform," remarked Dr. Robert Iannone, Head of Research & Development and Chief Medical Officer of Immunomedics. 

Bridgewater-based BioNJ Member Eli Lilly and Company and BioNJ Member Pfizer, with offices in Madison,  announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In the study, treatment with tanezumab 10 mg met the primary endpoint, demonstrating a statistically significant improvement in pain at 16 weeks compared to placebo.

BioNJ Member  Pfizer Inc., with offices in Madison, and  Ochsner Health System have entered into a multi-year strategic alliance to develop innovative models for clinical trials. Through this partnership, Pfizer and Ochsner -- through its innovation lab, innovationOchsner (iO), in partnership with Ochsner Research -- will explore ways to enhance the clinical trial experience and ease participation in clinical research for both patients and healthcare professionals.

Bridgewater-based BioNJ Member Sanofi etailed results were presented from two Phase 3 trials in patients with recurring severe chronic rhinosinusitis with nasal polyps (CRSwNP) despite previous treatment with surgery and/or systemic corticosteroids. These trials, known as SINUS-24 and SINUS-52, demonstrated that Dupixent® (dupilumab), when added to the standard of care corticosteroid nasal spray,  improved nasal polyp size, nasal congestion severity, chronic sinus disease, sense of smell and co-morbid asthma outcomes.

Princeton-based BioNJ Member Evotec AG and the Helmholtz Centre for Infection Research ("HZI") announced a collaboration with the goal to address a major global health threat by developing novel antibiotics that overcome drug-resistant bacterial pathogens. Research activities will initially be focused on the optimisation of cystobactamids, a family of natural antibacterial products with innovative chemical scaffolds that are active against the most dangerous Gram-negative pathogens on the WHO priority list.

Kenilworth-based BioNJ Member  Merck & Co. and  AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of LYNPARZA tablets, as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (BRCAm), who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.

Kenilworth-based BioNJ Member  Merck & Co. and  AstraZeneca announced positive results from the Phase 3 POLO trial.  Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with LYNPARZA versus placebo. The safety and tolerability profile of LYNPARZA was consistent with previous trials.
POLO is a randomized, double-blinded, placebo-controlled trial exploring the efficacy of LYNPARZA tablets as first-line maintenance monotherapy in patients with germline  BRCA-mutated (g BRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease has not progressed on platinum-based chemotherapy.

Kenilworth-based BioNJ Member  Merck & Co. announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection based on results from the EORTC1325/KEYNOTE-054 trialThis pivotal Phase 3 trial demonstrated that KEYTRUDA significantly prolonged recurrence-free survival (RFS), reducing the risk of disease recurrence or death by 43 percent compared to placebo in patients with resected, high-risk stage III melanoma (HR=0.57 [95% CI, 0.46, 0.70]; p<0.001). 

Kenilworth-based BioNJ Member  Merck & Co. announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma (RCC) at the 2019 Genitourinary Cancers Symposium. This is the first combination regimen to significantly improve overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared to sunitinib.

Kenilworth-based BioNJ Member  Merck & Co. and Immune Design announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design for $5.85 per share in cash for an approximate value of $300 million. "Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development," said Dr. Roger M. Perlmutter, President, Merck Research Laboratories.

Basking Ridge-based BioNJ Member Ipsen  has  struck  a $1.3 billion (€1.1 billion) deal to buy Clementia Pharmaceuticals for its late-phase rare disease drug palovarotene. The transaction will see Ipsen hand over $1 billion upfront to acquire the retinoic acid receptor gamma agonist ahead of a filing for FDA approval.  Canada's Clementia picked up the worldwide rights to palovarotene from Roche in 2013. 

Iselin-based BioNJ Member Helsinn announces that Helsinn Investment Fund S.A. has made a €1 Million investment in Gain Therapeutics SAGain Therapeutics SA is a private company, based in Lugano and with a branch in Barcelona, that exclusively licensed an advanced computational technology, Site-directed Enzyme Enhancement Therapy, (SEE-Tx®) used to identify next generation non-competitive pharmacological chaperones, under the scientific management of its inventor, Prof. Xavier Barril.

Princeton-based BioNJ Member Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies to treat Dry Eye Disease, announced a $93 million Series B financing. The round was co-led by Invus Opportunities and Flying L Partners in collaboration with Falcon Vision. Existing investors New Enterprise Associates (NEA) and Versant Ventures, as well as new investor Vida Ventures, participated significantly in the round.

Princeton-based BioNJ Member Taiho Oncology, Inc., in partnership with leading advocacy groups including Colorectal Cancer Alliance, Fight Colorectal Cancer and COLONTOWN®,  announced its support of a number of prevention and awareness initiatives during National Colorectal Cancer Awareness Month. Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer death in the United States, with an estimated 140,250 new cases and 50,630 deaths in 2018.

TheWell Bioscience  was recently welcomed as the newest tenant at  the Commercialization Center for Innovative Technologies (CCIT) in North Brunswick , a life sciences incubator owned by the New Jersey Economic Development Authority (NJEDA). From its new location at CCIT, the biotech company will further develop and scale its advanced 3D cell culture hydrogel system for drug screening, tissue engineering, and pre-clinical applications.

Bedminster-based Tyme Technologies, Inc. announced that it received design guidance for a registrational trial from the U.S. Food and Drug Administration (FDA) on a drug development pathway for SM-88 in third-line pancreatic cancer during a recent Type C meeting. The planned trial is intended to be a pivotal trial in the third-line setting to support a submission for FDA approval upon achievement of the trial endpoints and satisfaction of customary regulatory requirements.

Woodcliff Lake-based Eisai Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) to potentially update the label for BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily/BELVIQ XR (lorcaserin HCl) CIV once daily to include long-term efficacy and safety data from CAMELLIA-TIMI 61, a clinical trial of BELVIQ in 12,000 overweight and obese patients with cardiovascular (CV) disease and/or multiple CV risk factors such as type 2 diabetes mellitus (T2DM).

Bedminster-based  Mallinckrodt Pharmaceuticals  announced interim analysis results of its company-sponsored, Phase 3, single-arm, open-label, multi-center study assessing the efficacy of treating steroid-refractory, acute Graft-versus-Host Disease (aGvHD) pediatric patients with UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX® Photopheresis system. Given the overall response rate exceeded the specified target at the study midpoint, the company is electing not to proceed with further enrollment of additional patients in the clinical trial.

Bedminster-based Mallinckrodt Pharmaceuticals announced it has entered into a research collaboration agreement with Transimmune AG, a company developing novel immunotherapies based on its unique understanding of the physiologic processes underlying the activation of antigen-presenting cells. THERAKOS UVAR XTS®/CELLEX® Photopheresis is a medical procedure that is administered using U.S. FDA-approved UVADEX® (methoxsalen) Sterile Solution for the palliative treatment of skin manifestations associated with Cutaneous T-Cell Lymphoma (CTCL) in patients who are unresponsive to other forms of treatment.

Kyowa Kirin International PLC, with offices in Princeton, and Ultragenyx Pharmaceutical Inc. announced positive results of a 64-week efficacy and safety analysis of the randomized active-controlled Phase 3 study of Crysvita® (burosumab) in children with X-linked hypophosphatemia (XLH) compared with oral phosphate and active vitamin D (current conventional therapy). The new results showed that Crysvita was superior to conventional therapy for all key efficacy endpoints, showing a meaningful improvement in rickets severity, lower limb deformity, growth and physical functioning as demonstrated by increases in distance walked.

ARKAY Therapeutics has been named a finalist in the Most Successful Early Phase Research (Preclinical and Phase I) category in the CARE Awards, which recognize outstanding work across the global clinical research enterprise ARKAY Therapeutics is a privately-held, clinical stage biopharmaceutical company located in East Windsor, NJ.  ARKAY was recognized for its innovative product concept for developing clinically superior yet affordable products for Type 2 diabetes patients worldwide. 

Fair Lawn-based SK Biopharmaceuticals and Arvelle Therapeutics GmbH announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational antiepileptic drug for the potential treatment of partial-onset seizures in adult patients. "We are very pleased to enter into this licensing agreement with Arvelle, as it provides important validation of the global potential for cenobamate as a new treatment option for adults with partial-onset seizures," said Dr. Jeong Woo Cho, President and CEO of SK Biopharmaceuticals.

Hackensack-based  BrainStorm Cell Therapeutics Inc.  announced  Cleveland Clinic  as the first U.S. clinical site contracted for a planned Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with progressive Multiple Sclerosis (MS). The Phase 2 study (NCT03799718) will enroll progressive MS patients [Expanded Disability Status Scale (EDSS) 3.0-6.5] based on 2017 revised McDonald Criteria.

Lawrenceville-based Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of innovative medicines in immunology/inflammation and oncology, announced the appointment of Shashank Mahashabde as Vice President of Chemistry, Manufacturing and Controls (CMC) and Pablo Jimenez, M.D., FAPCR as Vice President and Therapeutic Area Head of Immunology. 

Morristown-based  Melinta Therapeutics, Inc.  announced the closing and receipt of the initial $75 million disbursement under the previously announced convertible loan facility from Vatera Healthcare Partners LLC on February 22, 2019 The company also announced that John H. Johnson has been appointed permanent Chief Executive Officer. Mr. Johnson had been serving as interim Chief Executive Officer since October 2018 and will continue to serve on the company's board of directors.

People in the News

Somerset-based Catalent  announced it has appointed Kay Schmidt to Senior Vice President, Technical Operations.  In this role, Ms. Schmidt will be responsible for leading a team and improving technology and operations at the company. Reporting to Alessandro Maselli, Ms. Schmidt will also focus on project management and managing Catalent's environmental, health, security and safety processes.

Institution and Education News

The Institute  for Life Science Entrepreneurship  at Kean University is joining the  CARB-X  Global Accelerator Network, an international consortium of committed scientists and experts working to develop new antibiotics, vaccines, diagnostics and other products to fight drug-resistant superbugs.  ILSE and CARB-X (Combating Antibiotic Resistant Bacterial Biopharmaceutical Accelerator) signed a three-year agreement under which ILSE will serve as an accelerator, providing drug discovery and diagnostics expertise, business strategy and other support to CARB-X's growing portfolio of innovative antibacterial development projects.

The  New Jersey Institute of Technology has been named a "Very High Research Activity" institution by the  Carnegie ClassificationNJIT is one of only three R1 research universities in New Jersey. Through specialized research centers and laboratories, NJIT conducted more than $162 million in research in 2018, an increase of $32 million since 2016, according to the school. In recent years, NJIT researchers have received numerous research awards, including 11 National Science Foundation CAREER awards. 

Hackensack  Meridian Health   Hackensack University Medical Center  announced it is the first hospital in the State to adopt the HeartFlow Analysis, a state-of-the-art noninvasive technology that aids physicians in the diagnoses of coronary artery disease.  In a statement, the medical center said that despite being the most common form of heart disease, studies have shown there is a need to improve how CAD is evaluated and diagnosed and that many of the noninvasive tests available today have low accuracy rates in detecting CAD.

Rider University has appointed certified public accountant James Hartman as its new Vice President for Finance/Treasurer and Chief Financial Officer. Mr.  Hartman most recently served as the Chief Financial Officer and Treasurer at  Bancroft Neurohealth . The $160 million non-profit consists of three schools, campus and community residential facilities, day and vocational programs and outpatient rehabilitation centers for children and adults with intellectual and developmental disabilities and traumatic brain injuries.

RWJBarnabas Health is restructuring its Southern Region and also announcing several changes in leadership, involving hospital, regional and corporate positions.  The announcement, by Barry H. Ostrowsky, President and Chief Executive Officer of RWJBarnabas Health (RWJBH), is effective immediately.  "These changes help to position us as a national leader in academic medicine, respond to the dynamically changing health care environment, and improve the health of our communities," stated Mr. Ostrowsky. 

Funding News

Following a recent evaluation of the program's performance in five Garden State Growth Zones (GSGZs), the New Jersey Economic Development Authority (NJEDA) Board acted to expand the Business Lease Incentive (BLI) program. The expanded program, which initially targeted the five GSGZs-Atlantic City, Camden, Trenton, Passaic and Paterson-will now be called the Small Business Lease Assistance Program and will include eight additional municipalities: Bridgeton, Jersey City, Millville, Mt. Holly, Phillipsburg, Plainfield, Salem and Vineland. 

The New Jersey Economic Development Authority (NJEDA) announced that PrimeWork and Incutate have been approved as the latest collaborative workspaces that can offer rent support to start-ups through NJ IgniteNJ Ignite supports technology and life sciences startups moving to a collaborative workspace by providing rent support which makes the lab and office space more affordable, providing the startup with greater access to environments where they can work alongside other growing companies. 

The New Jersey Economic Development Authority (NJEDA) announced that medical device manufacturer Carbon22 became the first start-up company to benefit from rent support through NJ Ignite. Carbon22 recently moved into a creative 'flex' office space at Building 78 of Kearny PointNJ Ignite helps startup companies realize the benefits of collaborative workspaces by providing up to nine months of rent support for startup technology and life sciences businesses that are moving to an approved collaborative workspace. 

The NJBAC is a state agency offering free and confidential assistance to help your business grow. As a "one-stop shop," NJBAC can help businesses of all sizes and types to manage the state's regulatory processes, boost exports, gain access to financial resources where applicable and tackle other obstacles along the way. You can download the NJBAC guide by clicking here or contact their business advocates at 1-800 JERSEY 7. 
Thought Leadership from BioNJ Members

We invite our Innovation and Associate Members at the Executive, Preferred and Market Maker levels to submit their white papers for consideration for this new section of the Weekender. Please submit papers to

In today's fast-paced marketplace and complicated  regulatory  environment, operating in the life sciences industry can bring a variety of challenges. BioNJ Member RSM has prepared these tools to help guide you.

Special Programs from Our Partners for BioNJ Members

March 5, 2019 | Philadelphia, PA

The Life Sciences Collaborative is proud to invite you to its 6th annual conference at University of the Sciences in Philadelphia.  Join along with reputable, top executives from the life sciences industry while speakers review: Navigating the Challenges of Completing an Initial Public Offering, Tackling Opioid Abuse and other Conditions with Innovative Treatments, CRO Opportunities in Alternative Therapies and more. Click here for more information and to register.

March 11, 2019 | Trenton
New Jersey State Museum, Main Room, 205 W State Street, Trenton, NJ

Industry representatives, Patients, families, caregivers, medical professionals and elected officials and their staff are invited to join us for Rare Disease Day 2019. Learn about real-world advocacy from New Jersey legislators, hear about the Patient journey from those who live it and enjoy a Keynote by First Lady Tammy Murphy.   Click here to register.

April 5, 2019 | Jersey City

Join leading experts and practitioners on April 5 for "The Future of Big Data: Artificial Intelligence and Machine Learning" -- 6th Annual New Jersey Big Data Alliance Symposium at New Jersey City University.  Explore  the impact and potential of Artificial Intelligence and Machine Learning in transforming business operations and driving new innovations.  Gain insights on cutting-edge research at New Jersey's premier academic institutions. Participate in relevant and valuable workshops.  Network  with industry, government, students, academic leaders and New Jersey Big Data Alliance members.

June 3-6, 2019 | Philadelphia Convention Center

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. The key benefits of attending the 2019 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought leaders with over 500 education sessions at your fingertips and unparalleled networking opportunities with 16,000+ attendees from 67 countries. 

June 9-14, 2019 | Drew University | Madison

NJ ResMed is a week-long graduate/professional-level course providing an accelerated program for medicinal chemists, biologists and other industrial and academic scientists who wish to broaden their knowledge of the drug discovery and development process. The course concentrates on the fundamentals of drug discovery spanning initial target validation through clinical development. More information and registration can be found at   

Please contact BioNJ at or call 609-890-3185 
with any questions.